Lipid-lowering, cardiovascular and anti-inflammatory effects of «Letium» in patients with hypertension.
Prof. M.N. Kochueva, prof. A.N. Korzh, PHD G.I. Kochuev, ass. V.A. Gavriluk, ass. O.A. Plehova. Kharkiv Medical Academy of Postgraduate Education, Kharkiv National Medical University.
This paper studied the dynamics of the lipid spectrum of blood and functional state of the endothelium of blood C-reactive protein (CRP) in patients with hypertension stage 1-2, which were additional factors of cardiovascular risk, under the influence of adjuvant therapy with the use of the drug Letium. 12-week therapy with the inclusion of Letium was accompanied by a statistically significant reduction in plasma total cholesterol, total TG, LDL cholesterol, atherogenic factor and increased levels of anti atherogenic HDL cholesterol.
Key Words: hypertension, C-reactive protein, lipid lowering therapy, endothelium vasodilatation.
Kochueva MN, Korzh AN, Kochuev GI, Gavriluk VA, Plehova OA. [Lipid-lowering, cardiovascular and anti-inflammatory effects of «Letium» in patients with hypertension]. Shidnoevr. z. vnutr. simejnoi med. 2014;1:78-85. Russian.
http://dx.doi.org/10.15407/internalmed2014.01.078
1. Kovalenko VM, Kornatskij VM, authors; Kovalenko VM, editor. Analitychno-statystychnyi posibnyk [Analitical and statistical tutorial]. K.: Derzhavna ustanova «NNTs Instytut kardiolohii imeni akademika M.D. Strazheska». 2013; 239. Ukrainian | ||||
2. Pospelov DL. Arterialnaia gipertenziia i serdechno-sosudistyi risk v prakticheskoi deiatelnosti vracha [Arterial hypertension and cardiovascular risk in doctor’s practice]. Ukraїnskii medichnii chasopis. 2013; 2 (94): 6—8. Russian | ||||
3. Horbas IM, Barna OM, Sakalosh VI. Otsinka poshyrenosti ta kontroliu faktoriv ryzyku sertsevo- sudynnykh zakhvoriuvan sered naselennia ta likariv. [Evaluation of widespread and control of risk factors of cardiovascular diseases among population and doctors]. Liky Ukrainy. 2010; (1): 4—9. Ukrainian | ||||
4. European society of hypertension. European society of cardiology. Klinichni rekomendatsii z arterialnoi hipertenzii Yevropeiskoho tovarystva hipertenzii (ESH) ta tovarystva kardiolohiv (ESC) 2013 roku [Clinical recommendations for arterial hypertension]. Arterialna hipertenziia. 2013; 4 (30): 160. Ukrainian | ||||
5. Sirenko YM, author. Arterialna hipertenziia ta suputnia patolohiia. [Arterial hypertension and comorbidities]. Donetsk: Vydavets Zaslavskyi O.I. 2010; 384. Ukrainian | ||||
6. Molchanova OA. Arterialnaia gipertenziia pri ozhirenii [Arterial hypertension in obesity]. Vrach. 2006; 3: 30—33. Russian | ||||
7. Rabmouni K, Correia ML, Haynes WG. [Obesity — associated Hypertension. New insights into mechanisms]. Hypertension. 2005; (45): 9—14. English | ||||
8. Thomas F, Bean K, Pannier B. [Cardiovascular Mortality in Overweight Subiects. The Key Role of Associated Risk Factor]. Hypertension. 2005; (46): 654—663. English | ||||
9. Guize L, Thomas F, Pannier B. [All-Cause Mortality Associated With Specific Combinations of the Metabolic Syndrome According to Recent Definitions]. Diabetes Care. 2007; 30: 2381—2387. English | ||||
10. Narkiewicz K. [Obesity and hypertension — the issue is more complex than we thought] Nephrol Dial Transplant. 2006; 21: 264—267. English | ||||
11. Thomas F, Bean K, Pannier B. [Cardiovascular Mortality in Overweight Subjects.The Key Role of Associated Risk Factors]. Hypertension. 2005; 46: 654—663. English | ||||
12. Neaton ID, Wentworth D. [Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group] Arch. Intern. Med. 1992; 152 (1): 56-64. English | ||||
13. Thanassoulis GI, Lyass A, Beniamin EI, Larson MG, Vita IA, Levy D, Hamburg NM, Widlansky ME, O’Donnell CI, Mitchell GF, Vasan RS. [Relations of exercise blood pressure response to cardiovascular risk factors and vascular function in the Framingham Heart Study] Circulation. 2012; 125(23):2836-2843. English | ||||
14. Barter P, Gotto AM, Rosa LI [HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events] The New England iournal of medicine. 2007; 357 (13): 1301—1310. English | ||||
15. Bezrodnaia LV. Arterialnaia gipertenziia i dislipidemiia. [Arterial hypertension and dyslipidaemia] Zdorovia Ukraїni.2007; 8: 28—29. English | ||||
16. Pavlova OS. Sovremennye vozmozhnosti effektivnoi serdechno-sosudistoi profilaktiki u patsientov s arterialnoi gipertenziei i dislipidemiei. [Moderm opportunities of effective cardiovascular prevention in patients with arterial hypertension and dyslipidaemia]. Meditsinskie novosti. 2012; (1): 62—68. Russian | ||||
17. Deivid DM, Sergio F, Makrae FL. Sovremennye perspektivy primeneniia statinov [Modern perspective of statin usage] Mezhdunarodnyi meditsinskii zhurnal. 2000; (6): 516—521. Russian | ||||
18. Sergienko IV. Istoriia poiavleniia statinov. [History of statins appearance]. Ateroskleroz i dislipidemii. 2011; 1: 57-66. Russian | ||||
19. Endo A, Kuroda M, Tanzawa К. [Competitive inhibition of 3-hydroxy-3-methylglutaryl сoenzyme A reductase by ML-236 and МL-236В, fungal metabolites having hypocholesterolemic activity]. FEBS Lett.1976; 72: 323—326. English | ||||
20. Endo A, Кuroda M, Tsuiita Y. [ML-236A, МL-236В and МL-236С, new inhibitors of cholesterogenesis produced by P.citrinum]. I. Antibiot.1976; 29(12): 1346 – 1348. English | ||||
21. Endo A, Komagata D, Shimada H, Monacolin M. [A new inhibitor of cholesterol biosynthesis]. Ibid. 1986; 39 (12): 1670—1674. English | ||||
19. Trutko SM, Shcherbakova VA, Ivanova IV. Vzaimosviaz putei biosinteza izoprenoidov i katabolizma istochnika ugleroda u anaerobnykh i fakultativno anaerobnykh bakterii. [Correlation of pathways of biosynthesis of isoprenoids and catabolism of carbon sourse in anaerobic and facultative anaerobic bacteria]. Mikrobiologiia. 2008; 77(3): 303—310. English | ||||
20. Zuzuk BM, Kutsik RV, Tomchuk I. Ginkgo biloba (analiticheskii obzor). [Ginkgo biloba (analytical review)]. Provizor. 2001; (19): 34. Russian | ||||
21. Iurev DV, Eller KI, Arzamastsev AP. Analiz flavonolglikozidov v preparatakh i BAD na osnove ginkgo biloba. [Analysis of phlavonolglycozides in preparations and BAD on basis of ginkgo biloba]. Farmatsiia. 2003; (2): 7. Russian | ||||
22. Kuznetsova SM, Glazovskaia II. Primenenie tanakana dlia neirofarmakologicheskoi reabilitatsii bolnykh, perenesshikh insult. [Use of tanakan for neuropharmacological rehabilitation of patients after stroke] In: [Tez. dokl materialy nauchno- prakticheskogo simpoziuma «Tanakan»]. Kiev.1997; 7. Russian | ||||
23. Bulaev VM. Klinicheskaia farmakologiia ekstrakta listev ginkgo biloba. [Clinical pharmacology of extract of leaves of ginkgo biloba]. Mediko-farmats. Vestnik. 1996; 8 (7): 33. Russian | ||||
24. Damulin IV, Zakharov VV, Elkin MN. Tanakan pri distsirkuliatornoi entsefalopatii. [Tanakan in neurovascular encephalopathy]. Klinich. Gerontologiia. 1996; (4): 51. Russian | ||||
25. Kleiinen I, Knipschild P [Ginkgo biloba] Lancet. 1992; 340 (7): 1136. | ||||
26. Balashova TS, Kubatiev AA. Vliianie tanakana na perekisne okislenie lipidov krovi i agregatsionnye svoistva trombotsitov u bolnykh insulinzavisimym sakharnym diabetom. [Influence of tanakan on peroxidation of blood lipids and aggregation properties of platelets. Terapevt. arkhiv.1998; 70 (12): 49. Russian | ||||
27. Celermaier DS, Sorensen KE, Bull C [Endotheliumdependent dilation in the systemic arteries of a symptomatic subiects relates to coronary risk factors and the interaction]. I. Am. Coll. Cardiol. 1994; 24: 1468—1474. English | ||||
28. Ivanova OV, Balakhonova TV, Soboleva GN, Atkov OI, Karpov IA. Sostoianie endoteliizavisimoi dilatatsii plechevoi arterii u bolnykh gipertonicheskoi bolezniu, otsenivaemoe s pomoshchiu ultrazvuka vysokogo razresheniia. [State of endotheliumdepedent dilatation of brachial artery in patients with arterial hypertension, evaluated by ultrasound of high resolution]. Kardiologia.1997; (7): 41—47. Russian | ||||
29. Ridker PM, Danielson E, Rifai N. [Blood pressure reduction, and C-reactive protein: primary report of theValMARC trial]. Hypertension. 2006; 48: 73—79. English | ||||
30. Ridker P, Glynn R, Hennekens C. [C-Reactive Protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial Infarction]. Circulation. 1998; 97: 2007—11. English | ||||
31. Reziapova NK, Kriukov NN, Kiseleva GI, Bogdanova IA. Izmenenie faktora Villebranda pri AG. [Changes of Villebrand factor in AG]. In: Rossiiskii natsionalnyi kongress kardiologov. M. 2007; 162. Russian | ||||
32. Kramareva VN, Lugovskoi EV. Pokazateli svertyvaiushchei sistemy krovi i protivotromboticheskie mekhanizmy u bolnykh essentsialnoi arterialnoi gipertenziei. [Indexes of blood clotting system and antithrombotic mechanisms in patients with essential hypertension]. Ukr. Med. Chasopis. 2010; 77 (3): 32—37. Russian | ||||
33. Blann A. [Von Willebrand factor and the endothelium in vascular disease]. Br. I. Biomed. Sci.1993; 50(2): 125—134. English | ||||
34. Balashova TS, Kubatiev AA. Vliianie tanakana na perekisne okislenie lipidov krovi i agregatsionnye svoistva trombotsitov u bolnykh insulinzavisimym sakharnym diabetom [Influence of tanakan on blood lipids peroxidation and aggregation properties of platelets in patients with insulin-dependent diabetes mellitus]. Terapevt. arkhiv.1998; 70(12): 49. Russian |